Hepcidin is described as the master regulator of iron: could its removal by CRRT lead to iron dysmetabolism in the critically ill?
Critical Care volume 24, Article number: 570 (2020)
Litton et al. noted that many of the risk factors for iron deficiency are also risk factors for developing a critical illness, and consequently, iron deficiency is likely to be over-represented in critically ill patients . Hepcidin is described as the master regulator of iron that determines the severity and duration of an iron-restricted state . Insufficient hepcidin levels are central to iron overload while hepcidin excess leads to iron restriction . A persistent state of iron dysmetabolism not only predisposes a vulnerable population to decreased erythropoiesis, but also has implications for the risk of nosocomial infection and critical illness-associated cognitive, neuromuscular, and cardiopulmonary dysfunction . A recent cohort study of 807 critically ill patients with acute kidney injury (AKI) requiring renal replacement therapy (RRT) found that both higher plasma concentrations of catalytic iron and lower concentrations of hepcidin are associated with increased mortality . A key question arising from this study is to what extent RRT contributes to iron dysmetabolism in critically ill patients. Fifty percent of critically ill patients develop AKI and 25% require RRT . Hepcidin and pro-hepcidin have molecular weights of 2700 Da and 10,000 Da, respectively, and, therefore, may be removed by continuous RRT (CRRT), which uses membranes with a cut-off of 35,000 Da . The protein-bound fraction of hepcidin is about 40%  which does not impede its elimination by convection or diffusion . It has been demonstrated that maintenance dialysis with both super-flux polysulphone (PS) and acrylonitrile 69 (AN69) membranes similarly removed hepcidin . Hemodialysis with PS membranes may achieve a high removal ratio of hepcidin by enhanced diffusion performance and an increased clearance of small molecule solutes, while AN69 membranes may remove hepcidin by adsorption . Indeed, hepcidin can be removed by diffusion, while in the case of pro-hepcidin, convection is the main mechanism . There are other factors to consider beyond RRT, and we should remain prudent regarding the therapeutic implications of RRT modalities at this early stage. The timing of iron administration in patients admitted to intensive care may also be a strong determinant of whether the benefits outweigh the risks . In addition, other factors such as bleeding in anticoagulated patients or clotting of dialysis membranes may limit iron accumulation in critically ill patients. A better understanding of the epidemiology and outcomes of iron metabolism during critical illness is needed before designing interventional studies looking at iron metabolism during CRRT.
Availability of data and materials
Renal replacement therapy
Acute kidney injury
Continuous renal replacement therapies
Litton E, Lim J. Iron metabolism: an emerging therapeutic target in critical illness. Crit Care. 2019;23(1):81 https://doi.org/10.1186/s13054-019-2373-1.
Leaf DE, Rajapurkar M, Lele SS, Mukhopadhyay B, Boerger EAS, McCausland FR, et al. Iron, hepcidin, and death in human AKI. J Am Soc Nephrol. 2019;30(3):493–504 https://doi.org/10.1681/ASN.2018100979.
Peters E, Antonelli M, Wittebole X, Nanchal R, François B, Sakr Y, et al. A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from The Intensive Care Over Nations audit. Crit Care. 2018;22(1):188 https://doi.org/10.1186/s13054-018-2112-z.
Diepeveen LE, Laarakkers CM, Peters HPE, van Herwaarden AE, Groenewoud H, IntHout J, et al. Unraveling hepcidin plasma protein binding: evidence from peritoneal equilibration testing. Pharmaceuticals (Basel). 2019;12(3):123 https://doi.org/10.3390/ph12030123.
Kuragano T, Furuta M, Shimonaka Y, Kida A, Yahiro M, Otaki Y, et al. The removal of serum hepcidin by different dialysis membranes. Int J Artif Organs. 2013;36(9):633–9 https://doi.org/10.5301/ijao.5000221.
We would like to thank Dr. Melissa Jackson for critical review of the manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare to have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Honore, P.M., Barreto Gutierrez, L., Kugener, L. et al. Hepcidin is described as the master regulator of iron: could its removal by CRRT lead to iron dysmetabolism in the critically ill?. Crit Care 24, 570 (2020). https://doi.org/10.1186/s13054-020-03295-6